Tumor necrosis factor a and its soluble receptors in rheumatic diseases: clinical and pathogenetic significance

1. <div><p>Алекперов Р. Т., Тимченко А. В., Самсонов М. Ю. и др. Уровень растворимых рецепторов 1типа фактора некроза опухоли а у больных системной склеродермией. Тер. архив, 2004, 5, 11-15.</p><p>Бородин А. Г. Клинико-патогенетическое значение спектра аутоантител и содержания фактора некроза опухоли- альфа при системной красной волчанке и некоторых ревматических заболеваниях. Авт. дисс. д. м. н., Ярославль, 2000.</p><p>Кричевская О.А., Клюквина Н.Г., Александрова Е.Н. и др. Клиническое значение растворимых рецепторов фактора некроза опухоли а у больных системной красной волчанкой. Клин, мед., 2004, 10, 51-55.</p><p>Насонов Е.Л. ФНОа - новая мишень для противовоспалительной терапии ревматоидного артрита. РМЖ, 2000, 17, 718-722.</p><p>Насонов ЕЛ., Чичасова Н.В., Самсонов М.Ю. и др. Растворимые рецепторы фактора некроза опухоли при ревматоидном артрите. Клин, мед., 2001, 8, 33-36.</p><p>Насонова В.А., Астапенко М.Г. Клиническая ревматология. М., Медицина, 1989, 143-175.</p><p>Степанец О.В. Клиническое значение растворимых рецепторов фактора некроза опухоли а 55 kDa при ревматоидном артрите. Авт.дисс.к.м.н, М., 2001.</p><p>Ярилин А.А. Система цитокинов и принципы ее функционирования в норме и патологии. Иммунол., 1997, 5, 714.</p><p>Aderka D., Wysenbeek A., Engelman Н. et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthr. Rheum., 1993,36. 1111-1120.</p><p>al-Janadi М., al-Balt S., al-Dalaan A. et al. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J. Clin. Immunol., 1993, 13, 58-67.</p><p>Aringcr М., Graninger W., Steiner G. at al. Safety and efficacy ofTNF-a blockade in SLE. Arthr. Rheum., 2004, 10, 3161-3169.</p><p>Aringer М., Smolen J. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthr. Res. Then, 2003, 5(4), 172-177.</p><p>Aukrust P., Liabak N.B., Miiller F. et al. Serum levels of tumor necrosis factor-a (TNF-a) and soluble TNF receptors in human immunodeficiency virus type I infection: Correlations to clinical immunologic and virologic parameters. J. Infect. Dis., 1994, 169,420­424.</p><p>Bargetzi M.J., Lantz М., Smit C.G.etal. Interleukin-I beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res., 1993, 53, 4010-4013.</p><p>Barrera P., Boerbooms A.M. Janssen E.M. et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine therapy. Arthr. Rheum., 1993, 36(8), 1070-1079.</p><p>Baud L., Ardaillou R. Tumor necrosis factor alpha in glomerular injury. Kidney Int., 1994, 45, 32-36.</p><p>Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 1996, 334, 1717-1725.</p><p>Bertolaccini M.L., Atsumi Т., Lanchbury J.S. et al. Plasma tumor necrosis factor alpha level and 238-A promoter polymorphism in patients with antophospholipid syndrome. Thromb. Haemost., 2001,85, 193-194.</p><p>Bolster M.B., Ludwicka A, Sutherland S.E. et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients wiih systemic sclerosis. Arthr. Rheum., 1997, 40(4), 743-751.</p><p>Brouckaert P., Fiers W. Tumor necrosis factor and the systemic inflammatory response syndrome. Curr. Top. Microbiol. Immunol., 1996, 216, 167-187.</p><p>Chu C.Q., Field М., Feldman M. et al. Localisation of tumor necrosis factor ? in synovial tissues and at cartilage-pannus junction in patients with rheumatoid arthritis, Arthr. Rheum., 1991, 34, 1125-1132.</p><p>Davas E.M., Tsirogianni A., Kappou I. et al. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srlL-2alpha levels and disease activity in systemic lupus erythematosus. Clin. Rheum., 1999, 18, 17-22.</p><p>Dayer J.M., Beutler B., Cerami A. Cachectintumor necrosis factor stimulate collagenase and prostaglandin E production by human synovial cells and dermal fibroblast. J. Exp. Med., 1985, 162, 2163-2168.</p><p>Engelberts I., Moeller A., Schoen G.J.M. et al. Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine, 1991, 10, 69-75.</p><p>Espersen G.T., Vfestergaard М., Ernst E. et al. Tumor necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation with disease activity. Clin. Rheum., 1991, 10, 374-376.</p><p>Fei G. Z., Svenungsson E., Padyukov L. et al. The A - 1087 ILI0 allele is associated with cardiovascular disease in SLE. Atheroscleros., 2004, 177(2), 409-414.</p><p>Frostegard J„ Svenungsson E., Gunnarsson I. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of TNF / tumor necrosis factor receptor system in SLE. Arthr. Rheum., 2003, 48(9), 2533-2540.</p><p>Gabay C., Cakir N., Moral F. et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J. Rheumatol., 1997, 24(2), 303-308.</p><p>Galtomo М., Picco P., Barbano G. et al. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schonlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications. J. Rheum., 1998,25, 361-365.</p><p>Gattorno М., Picco P., Buoncompagni A. et at. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann. Rheum. Dis., 1996, 55(4), 243247.</p><p>Georgopoulos S., Plows D., Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm., 1996, 46, 8697.</p><p>Gruschwitz M.S, Albrecht М., Vieth G. et al. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol., 1997, 24(10), 1936-1943.</p><p>Gruschwitz M.S, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interfer- on-gamma and tumor necrosis factor alpha in the early disease stage. Arthr. Rheum., 1997,40(3), 540-550.</p><p>Hasegawa М., Fujimoto М., Kikuchi K. et al. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol., 1997, 24(4), 663-665.</p><p>Hasegawa Y., Sawada М., Ozaki N. et al. Increased soluble tumor necrosis factor receptor levels in the serum of elderly people. Gerontol., 2000, 46(4), 185-188.</p><p>Heilig B., Fiehn C., Brockhaus M. et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J. Clin. Immunol., 1993, 13, 321-328.</p><p>Herrera-Esparza R., Barbosa-Cisneros O., Villalobos- Hurtado R-. et al. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus, 1998, 7, 154-158.</p><p>Kalechman Y., Gafler U., Da J.P. et al. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase inTNF-alpha levels. J. Immunol., 1997, 159, 2658-2667.</p><p>Kantor T.V. Friberg D., Medsger T.A. Jr. et al. Cytokine production and serum levels in systemic sclerosis. Clin. Immunol. Immunopathol., 1992, 65(3), 278-285.</p><p>Lacki J.K., Leszczynski P., Kelemen J. et al. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J. Med., 1997, 28, 99-107.</p><p>Lantz М., Bjomberg F., Olsson I. et al. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J. Immunol., 1994, 152, 1362-1369.</p><p>Majewski S., Wfojas-Pelc A., Malejczyk M. et al. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm, fenerol., 1999, 79(3), 207-210.</p><p>Riche F., Panis Y., Laisne M.J. et al. High tumor necrosis factor serum level is associated with increased survival in patients with abdominal septic shock: A prospective study in 59 patients. Surgery, 1996, 120, 801-807.</p><p>Robak E., Sysa-Jedrzejewska A., Dziankowska B. et al. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch. Immunol. Ther. Exp., 1998, 46, 375-380.</p><p>Steiner G., Studnicka-Benke A., Witzmann G. et al. Soluble receptor for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J. Rheumatol., 1995, 22, 406-412.</p><p>Studnicka-Benke A., Steiner G., Petera P. et al. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Brit. J. Rheum., 1996, 35, 1067-1074.</p><p>Suranyi M.G., Guasch A., Hall B.M. et al. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Amer. J. Kidney Dis., 1993, 21, 251-259.</p><p>Swaak A.J., van den Brink H.G., Aarden L.A. Cytokine production (IL-6 and TNF alpha) in whole blood cell cultures of patients with systemic lupus erythematosus. Scand. J. Rheum., 1996, 25, 233-238.</p><p>Tilz G.R., Diez-Ruiz A., Baier-Bitterlich G. et al. Soluble receptor for tumor necrosis factor and neopterin as parameters of cell- mediated immune activation. ACI International., 1997, 9, 110-118.</p><p>Man der Poll Т., van Deventer S.J.H., Hack C.E. et al. Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood, 1992, 79. 693-699.</p><p>van Zee K.J., Kohno Т., Fischer E. et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 4845-4851.</p><p>Wfeckmann A.L., Acocer-Varela J. Cytokine inhibitors in autoimmune disease. Semin. Arthr. Rheum., 1996, 26, 539-557.</p><p>Wilson A.G., Symons J.A., McDowell T.L. et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A., 1997,94, 3195-3199.</p></div><br />